KUPPUSAMY KARTHIK sold $1.6M of DGX

KUPPUSAMY KARTHIK (SVP, Clinical Solutions) sold 8,147 shares of QUEST DIAGNOSTICS INC (DGX) at $200.00 ($1.63M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KUPPUSAMY KARTHIK
Published Jun 8, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DGX
Neutral
medium confidence
Mentioned
$DGX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DGXNeutralLow
01

Why it matters

The newest concrete fact is the specific open-market sale size, price, and 10b5-1 status by a clinical solutions SVP; this can marginally influence sentiment but rarely drives fundamentals.

02

Market read

A $1.63M insider sale under 10b5-1 is a modest sentiment datapoint for DGX, with limited standalone trading impact.

03

What to watch

Traders should check whether DGX has concurrent fundamental catalysts (earnings, guidance, contract/regulatory updates) since Form 4 alone is usually low-signal.

Relevance 5/10Novelty 8/10Timing: Filed 2026-06-08; sale dated 2026-06-04

Background

The article is an SEC Form 4 insider transaction disclosure for Quest Diagnostics (DGX).

Company-level read

Ticker impact

$DGXNeutralMedium confidence
Context

Quest Diagnostics SVP Kuppusamy Karthik sold 8,147 shares (~$1.63M) in an open-market transaction under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived unless accompanied by other news.

Evidence & confidence

The filing is a disclosed sale (not a buy), but it is explicitly under a pre-arranged 10b5-1 plan, which typically reduces signal strength.

Market effects

Minimal; single-insider Form 4 selling does not reset sector fundamentals.

None indicated.

None indicated.

Counterpoint

Because the sale is on a 10b5-1 plan, it may reflect liquidity/tax planning rather than bearish expectations.

Key entities

  • Quest Diagnostics Inc.

    DGX, the company whose insider transaction was disclosed.

  • Kuppusamy Karthik

    SVP, Clinical Solutions; sold 8,147 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DGXLow

Quest Diagnostics Pays $13 Million to Settle Kickback Allegations Involving New York Giants Tickets

Quest Diagnostics will pay $13M to settle allegations of illegal kickbacks, including New York Giants tickets, to healthcare providers. The U.S. Attorney's Office claims the company violated the Anti-Kickback Statute from 2013 to 2022, offering perks in exchange for business referrals. Quest denies wrongdoing but agreed to a settlement and a 5-year compliance agreement.

$DGXLow

Quest Diagnostics pays more than $13M to settle alleged kickback scheme, federal prosecutors say

Quest Diagnostics agreed to pay $13M to settle allegations of a kickback scheme involving gifts to hospital executives, including New York Giants game tickets, according to federal prosecutors. The scheme allegedly lasted from 2013 to 2022, with Quest billing government-funded medical plans. The company will also face five years of auditing. Quest reported $11B in 2025 revenue, up 7%.

$DGXLow

Quest Diagnostics pays $13M to settle kickback allegations involving NY Giants tickets

Quest Diagnostics agreed to pay $13M to settle allegations of providing illegal kickbacks, including NY Giants tickets, to healthcare providers for referrals, according to the U.S. Attorney’s Office of New Jersey. The settlement resolves claims of violating the Anti-Kickback Statute and submitting false claims to Medicare and Medicaid. Quest denies wrongdoing but agreed to the settlement to resolve the matter.

$DGXLow

Quest Diagnostics pays more than $13 million to settle allegations of illegal kickbacks involving Giants tickets, VIP events

Quest Diagnostics Inc. paid $13,014,576 plus interest to settle federal allegations of illegal kickbacks involving free New York Giants tickets and VIP events to induce patient referrals. The company violated the Anti-Kickback Statute and submitted false claims to Medicare and Medicaid programs, according to the U.S. Attorney’s Office. Quest also entered a five-year Corporate Integrity Agreement with HHS-OIG. Whistleblowers will receive nearly $2.5 million.

$LHMed

Labcorp, Quest urge RESULTS Act passage as lab payment cuts loom

Labcorp and Quest Diagnostics warn of revenue impacts from upcoming Medicare and Medicaid reimbursement cuts starting in 2027. Labcorp expects a $125 million hit, while Quest estimates a 1% revenue reduction in 2026. Both companies advocate for the passage of the RESULTS Act to reform the payment rate-setting process, citing concerns over patient access and lab viability.